FDA
Dabigatran Etexilate Mesylate
The FDA lists this product in 33 strengths and forms.
Composition
- Active ingredients
- DABIGATRAN ETEXILATE MESYLATE EQ 150MG BASE
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- DABIGATRAN ETEXILATE MESYLATE EQ 110MG BASE · CapsuleANDA208070-002 · Prescription
- DABIGATRAN ETEXILATE MESYLATE EQ 150MG BASE · CapsuleANDA208070-003 · Prescription
- DABIGATRAN ETEXILATE MESYLATE EQ 75MG BASE · CapsuleANDA208070-001 · Prescription
- DABIGATRAN ETEXILATE MESYLATE EQ 150MG BASE · CapsuleANDA207961-002 · Prescription
- DABIGATRAN ETEXILATE MESYLATE EQ 110MG BASE · CapsuleANDA207961-003 · Prescription
- DABIGATRAN ETEXILATE MESYLATE EQ 75MG BASE · CapsuleANDA207961-001 · Prescription
- DABIGATRAN ETEXILATE MESYLATE EQ 75MG BASE · CapsuleANDA207984-001 · Tentative approval
- DABIGATRAN ETEXILATE MESYLATE EQ 110MG BASE · CapsuleANDA207984-002 · Tentative approval
- DABIGATRAN ETEXILATE MESYLATE EQ 150MG BASE · CapsuleANDA207984-003 · Tentative approval
- DABIGATRAN ETEXILATE MESYLATE EQ 150MG BASE · Capsule
At a glance
- Brand name
- Dabigatran Etexilate Mesylate
- Route
- Oral
- Dosage form
- Capsule
- Applicant
- Alembic Pharms LTD
- Status
- Tentative approval
- FDA approval
- 4 Apr 2022
- Application
- ANDA208046-001